Romagnoli P, Germain R N
Lymphocyte Biology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-1892, USA.
J Exp Med. 1995 Dec 1;182(6):2027-36. doi: 10.1084/jem.182.6.2027.
Calnexin is a resident protein of the endoplasmic reticulum (ER) that associates with nascent protein chains. Among the newly synthesized integral membrane proteins known to bind to calnexin is invariant chain (Ii), and Ii release from calnexin coincides with proper assembly with major histocompatibility complex (MHC) class II heterodimers. Although calnexin association with several membrane glycoproteins depends on interactions involving N-linked glycans, we previously reported that a truncation mutant of mouse Ii (mIi1-107) lacking both N-glycosylation sites was highly effective in associating with MHC class II heterodimers and escorting these dimers through the secretory pathway. This could indicate that calnexin, despite binding to both Ii and class II, is not necessary for the proper interaction of these proteins, or that in contrast to most membrane glycoproteins, the N-linked glycans of Ii are not critical to its interaction with this chaperone. To examine this issue, we have directly explored the binding of calnexin to both Ii truncation mutants lacking the typical sites of N-glycosylation or Ii produced in cells treated with tunicamycin to prevent glycan addition. These experiments revealed that either method of eliminating N-linked carbohydrates on Ii also inhibited association with calnexin. A lumenally truncated form of Ii (mIi1-131) that still has N-linked carbohydrates showed a decreased affinity for calnexin compared with intact Ii, however, indicating that calnexin-Ii binding is not determined solely by the sugar moieties. All forms of Ii lacking N-linked sugars and showing defective association with calnexin also had enhanced rates of preendosomal degradation. Despite this effect on degradation rate, tunicamycin treatment did not inhibit the association of class II with glycan-free Ii. These data support the view that calnexin is not an absolute requirement for the proper assembly of class II-Ii nonamers, but rather acts primarily to retain Ii in the ER and to inhibit its degradation. These two properties of calnexin-Ii interaction may help ensure that sufficient intact Ii is available for efficient inactivation of the binding sites of newly synthesized class II molecules, while limiting the ability of excess free Ii to alter the transport properties of the early endocytic pathway.
钙连蛋白是内质网(ER)的一种驻留蛋白,它与新生的蛋白质链相关联。在已知与钙连蛋白结合的新合成的整合膜蛋白中,有恒定链(Ii),并且Ii从钙连蛋白上的释放与它和主要组织相容性复合体(MHC)II类异二聚体的正确组装相吻合。尽管钙连蛋白与几种膜糖蛋白的结合依赖于涉及N-连接聚糖的相互作用,但我们之前报道过,缺乏两个N-糖基化位点的小鼠Ii截短突变体(mIi1-107)在与MHC II类异二聚体结合以及护送这些二聚体通过分泌途径方面非常有效。这可能表明,尽管钙连蛋白与Ii和II类都结合,但它对于这些蛋白质的正确相互作用并非必需,或者与大多数膜糖蛋白相反,Ii的N-连接聚糖对其与这种伴侣蛋白的相互作用并不关键。为了研究这个问题,我们直接探究了钙连蛋白与缺乏典型N-糖基化位点的Ii截短突变体或在用衣霉素处理以防止聚糖添加的细胞中产生的Ii之间的结合。这些实验表明,消除Ii上N-连接碳水化合物的任何一种方法也会抑制其与钙连蛋白的结合。然而,仍然具有N-连接碳水化合物的内腔截短形式的Ii(mIi1-131)与完整的Ii相比,对钙连蛋白的亲和力降低,这表明钙连蛋白与Ii的结合并非仅由糖部分决定。所有缺乏N-连接糖且与钙连蛋白结合有缺陷的Ii形式,其在内体前降解的速率也有所提高。尽管对降解速率有这种影响,但衣霉素处理并未抑制II类与无糖基化的Ii的结合。这些数据支持这样一种观点,即钙连蛋白对于II类-Ii九聚体的正确组装并非绝对必需,而是主要起到将Ii保留在内质网中并抑制其降解的作用。钙连蛋白与Ii相互作用的这两个特性可能有助于确保有足够的完整Ii可用于有效灭活新合成的II类分子的结合位点,同时限制过量游离Ii改变早期内吞途径运输特性的能力。